Safety and efficacy of isolated limb perfusion in elderly melanoma patients

[1]  P. Schlag,et al.  Treatment of melanoma in-transit metastases confined to the limb , 1996, Acta Chirurgica Austriaca.

[2]  J. Leung,et al.  Relative Importance of Preoperative Health Status Versus Intraoperative Factors in Predicting Postoperative Adverse Outcomes in Geriatric Surgical Patients , 2001, Journal of the American Geriatrics Society.

[3]  A. Hart,et al.  Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  L. Goldman,et al.  Impact of Age on Perioperative Complications and Length of Stay in Patients Undergoing Noncardiac Surgery , 2001, Annals of Internal Medicine.

[5]  A. Eggermont,et al.  Systemic Toxicity and Cytokine/Acute Phase Protein Levels in Patients After Isolated Limb Perfusion With Tumor Necrosis Factor-a Complicated by High Leakage , 2000, Annals of Surgical Oncology.

[6]  A. Eggermont,et al.  Absence of Severe Systemic Toxicity After Leakage-Controlled Isolated Limb Perfusion With Tumor Necrosis Factor-α and Melphalan , 1999, Annals of Surgical Oncology.

[7]  S. Ariyan,et al.  Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. , 1998, Surgery.

[8]  M. Zenilman,et al.  Surgery in the elderly. , 1998, Current problems in surgery.

[9]  K. Hammermeister,et al.  Risk adjustment of the postoperative morbidity rate for the comparative assessment of the quality of surgical care: results of the National Veterans Affairs Surgical Risk Study. , 1998, Journal of the American College of Surgeons.

[10]  S. Libutti,et al.  Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics , 1997, Cancer.

[11]  F. Grover,et al.  Risk adjustment of the postoperative mortality rate for the comparative assessment of the quality of surgical care: results of the National Veterans Affairs Surgical Risk Study. , 1997, Journal of the American College of Surgeons.

[12]  C. Wiltschke,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Brennan,et al.  Factors predicting hospitalization after operative treatment for gastric carcinoma in patients older than 70 years. , 1997, Journal of the American College of Surgeons.

[14]  B. Vrouenraets,et al.  Thirty‐five years of isolated limb perfusion for melanoma: Indications and results , 1996, The British journal of surgery.

[15]  A. Eggermont,et al.  Systemic toxicity after isolated limb perfusion with melphalan for melanoma. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  C. Garbe,et al.  Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile , 1996 .

[17]  D. Fraker,et al.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Garbe,et al.  Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile? , 1996, European journal of cancer.

[19]  D. Coit.  Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion. , 1995, The cancer journal from Scientific American.

[20]  C. Ritchie,et al.  Preoperative Assessment of Older Adults , 1995, Journal of the American Geriatrics Society.

[21]  J. Hermans,et al.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients , 1995, The Lancet.

[22]  A. Eggermont,et al.  Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. , 1995, Archives of surgery.

[23]  P. Mcaleese,et al.  The Effect of Complications on Length of Stay , 1994, Annals of surgery.

[24]  A. Hart,et al.  Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. , 1994, Journal of the American College of Surgeons.

[25]  A. Eggermont,et al.  Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. , 1993, American journal of surgery.

[26]  J. Klaase,et al.  Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma , 1992 .

[27]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. V. van Geel,et al.  Functional morbidity after regional isolated perfusion of the limb for melanoma , 1989, Cancer.

[29]  K. Hobler.  Colon Surgery for Cancer in the Very Elderly: Cost and 3‐Year Survival , 1986, Annals of surgery.

[30]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[31]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .